Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.850
0.00 (0.00%)
At close: May 22, 2026, 4:00 PM EDT
1.900
+0.050 (2.70%)
After-hours: May 22, 2026, 7:19 PM EDT
Neumora Therapeutics Employees
Neumora Therapeutics had 96 employees as of December 31, 2025. The number of employees decreased by 14 or -12.73% compared to the previous year.
Employees
96
Change
-14
Growth
-12.73%
Revenue / Employee
n/a
Profits / Employee
-$2,316,604
Market Cap
337.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 96 | -14 | -12.73% |
| Sep 30, 2025 | 95 | -14 | -12.84% |
| Jun 30, 2025 | 96 | -12 | -11.11% |
| Mar 31, 2025 | 103 | -17 | -14.17% |
| Dec 31, 2024 | 110 | -14 | -11.29% |
| Sep 30, 2024 | 109 | -1 | -0.91% |
| Jun 30, 2024 | 108 | -2 | -1.82% |
| Mar 31, 2024 | 120 | 12 | 11.11% |
| Dec 31, 2023 | 124 | 30 | 31.91% |
| Jun 30, 2023 | 110 | 16 | 17.02% |
| Mar 31, 2023 | 108 | 14 | 14.89% |
| Dec 31, 2022 | 94 | 6 | 6.82% |
| Mar 31, 2022 | 94 | 41 | 77.36% |
| Dec 31, 2021 | 88 | 35 | 66.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| REGENXBIO | 371 |
| Rocket Pharmaceuticals | 202 |
| Puma Biotechnology | 179 |
| Verastem | 102 |
| Lineage Cell Therapeutics | 77 |
| Larimar Therapeutics | 71 |
| Rezolute | 68 |
NMRA News
- 3 days ago - Neumora Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 10 days ago - Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 15 days ago - Neumora Therapeutics reports Q1 EPS (30c), consensus (31c) - TheFly
- 16 days ago - Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 16 days ago - Neumora Therapeutics Earnings release: Q1 2026 - Filings
- 16 days ago - Neumora Therapeutics Slides: Q1 2026 - Filings
- 16 days ago - Neumora Therapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Neumora Therapeutics Proxy statement: Proxy filing - Filings